Loading, Please Wait...
GLASGOW, SCOTLAND--(Marketwired - Jan 25, 2016) - HCi Viocare Clinics, a subsidiary of HCi Viocare (
HCi Viocare Clinics participates with a stand within the Scottish Pavilion, with interest in presenting its Prosthetic and Orthotic Clinic model to the Arab market.
The company is setting up a chain of full service prosthetic, orthotic and diabetic foot rehabilitation clinics across the Mediterranean Europe and the Middle East. The clinics operate according to British and International standards and provide a truly personalized quality of care for its clients.
HCi Viocare operates a state-of-the-art clinic in Glasgow, Scotland, with a strong heritage and the highest standards of care that serves as the centre of reference and training for the chain.
With a multidisciplinary team of experts, and a continuous update of technological know-how and practical expertise, the clinic delivers the highest quality in personalized services and product. The 500m2 facility houses a fully equipped consultation and rehabilitation service provided with excellent comfort and functionality, and also a state-of-the-art workshop, to provide rapid on-site manufacturing of prosthetic and orthotic solutions.
Heleen Kist, HCi Viocare's Chief Operating Officer stated: "Our Company is dedicated to improving the health and wellbeing of people across the ability and activity spectrum, helping them to be as fit and active as they can be. Our participation at Arab Health 2016 not only supports our goal to increase our partnership contacts in the Middle East region, but also provides us with the opportunity to share our excellence in care and our client-centric model."
About HCi Viocare Clinics
The company is a Glasgow-based subsidiary of HCi Viocare , which has a dual, complementary business model of 1) creating the first cross-border independent chain of Prosthetics & Orthotics (P&O) and Diabetic Foot clinics in Europe and the Middle East and 2) developing a portfolio of biomedical technologies to address unmet needs in the diabetic foot, P&O and other health & wellbeing areas, for licensing to established industry participants. HCi Viocare is listed in the OTC Markets in the USA, has its executive office in Athens, Greece and R&D centre in Glasgow, UK.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects", "intends", "estimates", "projects", "anticipates", "believes", "could", and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates will occur in the future are forward-looking statements, including but not limited to future developments in the areas of athletic shoes and the information and performance of the company's technology in such applications. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company recently acquired its first operational Prosthetics & Orthotics (P&O) clinic and is continuing development efforts for its other biomedical technologies, including a "smart insole" with several potential applications. There is no assurance that the Company will be successful in its ongoing expansion and development efforts, or that it will find suitable commercialization partners for its technologies. Except as required by law, HCi Viocare disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that HCi Viocare files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
Weber Shandwick Athens
T: + 30 210 8171100 / 210 8171276